Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas

通过合作进行治愈：利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤

• 批准号: 10566833
• 负责人: DEBORAH STEPHENS
• 金额: $ 8.38万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-06 至 2023-08-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10566833
• 关键词: Adult; Advisory Committees; Advocate; Award; B-Cell Lymphomas; Caring; Catchment Area; Chronic Lymphocytic Leukemia; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Community Health Education; Community Outreach; Dedications; Development; Early Therapeutic-Clinical Trials Network; Fellowship; Funding; Grant; Hematological Disease; Hematology; Hematopoietic Neoplasms; Industry; International; Kentucky; Lead; Leadership; Longterm Follow-up; Lymphoma; Malignant Neoplasms; Mantle Cell Lymphoma; Mentorship; National Cancer Institute; Ohio; Outcome; Patient Care; Patients; Phase I/II Clinical Trial; Physicians; Principal Investigator; Protocols documentation; Publishing; Refractory; Relapse; Research; Research Institute; Research Personnel; Research Scientist Award; Review Committee; Role; Scientist; Small-Cell Lymphoma; Southwest Oncology Group; Specialist; Therapeutic; Time; Translations; Underrepresented Minority; Universities; Woman; Work; clinical investigation; fighting; improved; investigator-initiated trial; leukemia; leukemia/lymphoma; meetings; member; patient navigation; professor; programs; recruit; standard of care; therapy resistant; working group

PROJECT SUMMARY/ABSTRACT Deborah Stephens, DO is an Assistant Professor (to be Associate in July 2022) at the Huntsman Cancer Institute (HCI) who focuses on clinical investigation for patients with chronic lymphocytic leukemia (CLL) and B- cell lymphoma, the most common adult blood cancers. Despite recent advances in the field, CLL and relapsed/refractory B-cell lymphomas are mostly considered incurable. Resistance to therapy is common resulting in poor clinical outcomes. Dr. Stephens’s research is focused on CLL and lymphoma patient care and survival through development and management of a clinical trial portfolio at HCI that includes National Cancer Institute (NCI)-sponsored investigator-initiated trials. The scope of this program is significant, improves the care of local patients and has produced has changed the standard of care for patients internationally. Through several national and local leadership roles, Dr. Stephens dedicates 40% of her time to performing and promoting NCI-sponsored clinical trials. This work, currently not funded, would be supported by the R50 Research Scientist award and support the continuation and development of Dr. Stephens’s work. She is the CLL Lead for the SWOG Leukemia Working Group, which encompasses her roles as the national principal investigator (PI) for the S1925 EVOLVE CLL trial (NCT04269902) and leader of a task force to develop the next SWOG trial for CLL patients. Through the SWOG Lymphoma Working Group, Dr. Stephens has analyzed and published (as first author) the long-term follow-up of several pivotal lymphoma studies. She serves as the local PI for numerous NCI-sponsored CLL and lymphoma studies, which has resulting in placing HCI among leaders in national accrual in several studies including S1925, EA9161, and A041702 (CLL) and EA4151 and EA4181 (mantle cell lymphoma). At HCI, she serves on several committees dedicated to hematology clinical research, including HCI Hematology Disease Center (Interim Director), Hematology Clinical Trials Research Group (Physician Leader), Independent Protocol Review Committee (member), and the Center for Investigational Therapeutics (member). Building upon connections from her fellowship and extensive clinical trial collaboration with investigators at The Ohio State University (OSU), she developed a partnership with OSU and the University of Kentucky that enabled HCI’s successful UM1 ETCTN program application and resulted in grant 60075822 (Carson). She serves as the Hematology Expert for HCI on the ETCTN Executive Committee. The R50 Grant, would support Dr. Stephens to continue her work and plans for meeting the objectives of the NCI-funded clinical trials research program by (1) translation of HCI research into NCI-sponsored clinical trials and expand collaborative grant opportunities through advocating for targeted recruitment of key collaborating scientists, (2) expanding access to phase 1/2 clinical trials to all patients in HCI’s catchment areas, and (3) increasing the number of under-represented minorities and women through collaborations with HCI’s Community Outreach and Education and Patient Navigation Programs.

项目总结/摘要 黛博拉斯蒂芬斯，DO是亨茨曼癌症研究所的助理教授（将于2022年7月成为副教授） 该研究所（HCI）专注于慢性淋巴细胞白血病（CLL）和B- 细胞淋巴瘤，最常见的成人血癌。尽管该领域最近取得了进展，但CLL和 复发性/难治性B细胞淋巴瘤大多被认为是不可治愈的。对治疗的抵抗很常见 从而导致不良的临床结果。斯蒂芬斯的研究重点是慢性淋巴细胞白血病和淋巴瘤患者的护理， 通过开发和管理HCI的临床试验组合，包括国家癌症研究所， 美国国家癌症研究所（NCI）申办的药物启动试验。该计划的范围很大，改善了 护理本地病人，并已产生了改变了护理标准的病人在国际上。 通过几个国家和地方的领导作用，斯蒂芬斯博士致力于她的时间的40%，以执行 以及推广国家癌症研究所赞助的临床试验。这项工作目前没有资金，将得到R50的支持。 研究科学家奖和支持斯蒂芬斯博士的工作的延续和发展。她是 CLL领导SWOG白血病工作组，其中包括她作为国家负责人的角色 S1925 EVOLVE CLL试验（NCT 04269902）的研究者（PI）和开发 CLL患者的下一个SWOG试验。通过SWOG淋巴瘤工作组，斯蒂芬斯博士分析 并发表了（作为第一作者）几项关键淋巴瘤研究的长期随访。她作为 许多NCI申办的CLL和淋巴瘤研究的当地PI，这导致将HCI置于 在包括S1925、EA 9161、A041702（CLL）和EA 4151在内的多项研究中， EA 4181（套细胞淋巴瘤）。在HCI，她担任几个委员会致力于血液学临床 研究，包括HCI血液病中心（临时主任），血液学临床试验研究 小组（医师负责人）、独立方案审查委员会（成员）和中心 研究治疗学（成员）。建立在她的奖学金和广泛的临床 在与俄亥俄州州立大学（OSU）的研究人员进行试验合作时，她与OSU建立了伙伴关系 和肯塔基州大学，使HCI的成功UM 1 ETCTN程序的应用，并导致 授权60075822（卡森）。她担任ETCTN执行委员会HCI的血液学专家。 R50赠款将支持斯蒂芬斯博士继续她的工作和计划，以实现以下目标： NCI-funded clinical trials research program by（1）将HCI研究转化为NCI-sponsored clinical trials 试验和扩大合作赠款机会，倡导有针对性地征聘关键的 合作的科学家，（2）扩大进入1/2期临床试验的所有患者在HCI的集水区 （3）通过与少数民族和妇女的合作， HCI的社区外展和教育以及患者导航计划。